AI

Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will  be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of multiple selective CDK7 compounds. The […]

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey by GlobalData, a data and […]

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform to design a novel class […]

Optibrium has published a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”, working alongside Takeda Pharmaceuticals’ proprietary global dataset and the Alchemite deep learning method. The study demonstrated that deep learning generates new and valuable insights on global pharma-scale, high-value and proprietary datasets. Such datasets are complex, with data deriving […]

EQRx and Exscientia are collaborating to combine the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates and expand EQRx’s pipeline of novel therapies. This collaboration is focused on creating improvements in the traditional drug discovery and development processes by improving the probability of success through each company’s capabilities to […]

The global artificial intelligence (AI) in drug discovery market size is expected to reach US$4.05 billion by 2028 according to a new study by Polaris Market Research. The report “Artificial Intelligence in Drug Discovery Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease, Others); By Application; By Regions; […]

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in 2019. Exscientia will take responsibility […]

The latest episode of the free DDW podcast is out, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh. Dr Chouchane is a professor in the departments […]

This is the latest episode of the free DDW podcast, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh, who discuss the value of biobanks, artificial intelligence and […]

Valence’s co-founder and CEO, Daniel Cohen, spoke to Lu Rahman about the company’s plan to empower drug discovery scientists with AI-enabled drug design LR:  Outline of the company and its main initiatives DC: Valence is an interdisciplinary team of scientists and engineers out of Mila, the world’s largest deep learning research institute. At Valence, we […]

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s next generation 3-D evolutionary AI-design […]

Charles River Laboratories and Valence Discovery have teamed up to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimisation. Building on research done by Valence’s founding team at Mila, a deep learning research institute, the Valence platform enables the design of small molecule drug candidates in novel […]

Welcome to the Future of Drug Discovery. Welcome to Arctoris from Arctoris on Vimeo. Arctoris is a global platform company headquartered in Oxford, UK that is transforming drug discovery by combining robotics and AI. Arctoris developed and operates Ulysses, a fully automated drug discovery platform. Ulysses has been created to address fundamental problems with conventional […]

Antiverse, a biotechnology company developing a computational antibody drug discovery platform, has raised seed funding totalling £1.4 million ($2 million USD), comprising new investment and match funding from the UKI2S Innovate Accelerator. The funding will be used to further develop Antiverse’s AI antibody drug discovery platform, which rapidly and accurately predicts antibody-antigen binding to identify […]

Phesi, provider of AI-based clinical development analytics products and solutions, is showcasing its data-driven clinical development approach at SCOPE Virtual Summit for Clinical Operations Executives 2021, in a case study session with international pharmaceutical company, Alfasigma. Phesi and Alfasigma are currently working together to maximise the value of priority medical assets, explore the use of […]

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as PerkinElmer, Thermo Fisher Scientific and […]